What Is KPV?

Published August 2026 · Patriot Labs Research Team · ~12 min read

What KPV is

KPV is a tripeptide. The name is not an acronym or a project code — it is the single-letter sequence itself: K for lysine, P for proline, V for valine, joined in that order. Three residues is about the smallest thing that still earns the word "peptide"; for background, see what peptides are.

What makes those particular three worth a guide is where they come from. They are the last three of α-melanocyte-stimulating hormone (α-MSH), a 13-residue hormone whose sequence, given verbatim in the primary literature, is SYSMEHFRWGKPV. Read the last three letters. That is why KPV is conventionally written α-MSH(11–13).

α-MSH is itself a fragment of something larger. The human proopiomelanocortin entry in UniProt (accession P01189) annotates α-MSH as residues 138–150 of the precursor protein, released by proteolytic processing. By simple arithmetic, KPV therefore corresponds to residues 148–150 of proopiomelanocortin — a fragment of a fragment.

That lineage separates KPV from most of the catalog. Many research peptides are designed molecules — analogues with non-natural substitutions, half-life motifs, fragments fused by medicinal chemists. KPV is none of those. It is a naturally occurring stretch of a human hormone, isolated and studied on its own. It also appears as one of four components in the KLOW blend, which covers it briefly as a blend component; this guide goes underneath that.

The fragment and the parent hormone

The central claim in the KPV literature is a dissociation claim, and everything else rests on it. α-MSH does at least two distinguishable things. It is the classical pigmentation signal — the "melanocyte-stimulating" in its name is literal. It is also an anti-inflammatory signalling molecule. A 2021 review in Pharmaceuticals describes α-MSH as acting "by suppression of proinflammatory mediators such as TNF-α" and by "induction of cytokine suppression by production of IL-10," and reports that "α-MSH nullified TNF-mediated NF-κB activation."

The interesting result is what survives truncation. The same review states that "C-terminal tripeptide derivatives of α-MSH (e.g., KPV (Lys-Pro-Val, the C-terminal sequence of alpha-MSH)…possess anti-inflammatory properties with no pigmentary effects." In other words, the two activities come apart: cut the hormone down to its last three residues and the anti-inflammatory arm is reported to persist while the pigmentary arm does not.

That is the whole reason a three-residue fragment gets studied at all rather than the intact hormone. If the fragment were simply a weaker version of the parent there would be no point. The claim is that it is a narrower one. Two chemical details deserve more precision than they usually get.

The C-terminus is not automatically the same molecule. UniProt annotates position 150 of proopiomelanocortin — the terminal valine of α-MSH, and therefore the V of KPV — as valine amide, and position 138 as N-acetylserine. Inside the hormone, that valine carries an amide, not a free carboxylate. A synthetic tripeptide can be made either way — free acid or C-terminal amide (KPV-NH₂) — and the two are chemically distinct compounds. A certificate of analysis is the only place a given lot's identity is actually established; see understanding peptide COA testing.

The residue numbering has drifted in secondary sources. The primary papers write α-MSH(11–13): the 2008 Inflammatory Bowel Diseases study says "the melanocortin-derived tripeptide α-MSH(11–13) (KPV)," and the 2000 Journal of Leukocyte Biology antimicrobial paper writes "its carboxy-terminal tripeptide (11–13, KPV)." A 2023 review in Cells writes "α-MSH(11-14)." The sequence settles it — a 13-residue peptide has no residue 14 — but the discrepancy is worth knowing so it does not read as two different molecules.

Two accounts of how it acts

There are two threads in the literature, and they are not fully reconciled. Reporting only one would misrepresent the field.

Thread one: receptor-mediated signalling. The melanocortins act through a family of five G-protein-coupled receptors, MC1R through MC5R. The 2021 Pharmaceuticals review describes the inhibitory effect of α-MSH as "performed through cAMP production," assigns MC3R a role in efferocytosis, and states that "immunomodulatory effects of α-MSH in T-cells is mediated through MC5R." MC1R is the receptor most often invoked in the inflammation literature. If KPV is a shortened melanocortin, the natural hypothesis is that it engages some part of the same receptor system, less efficiently than the intact hormone.

Thread two: receptor-independent effects. The evidence against a purely receptor-driven story is direct. The 2008 Inflammatory Bowel Diseases study tested KPV in MC1Re/e mice, a strain in which melanocortin-1 receptor function is lost: "In MC1Re/e mice, KPV treatment rescued all animals in the treatment group from death during DSS colitis." An effect that survives loss of a receptor is not an effect that requires it.

The 2023 Cells review reads the same data more cautiously than a headline would, noting that KPV showed diminished therapeutic impact in MC1R-mutant animals despite the survival benefit, and concluding that "there are probably MC1R-dependent and -independent mechanisms by which the KPV peptide may act therapeutically in experimental colitis." That is the accurate summary: not "KPV does not use receptors," but "receptors are not the whole explanation."

The receptor-independent route that has attracted most attention is not a signalling receptor at all but a transporter. The 2021 Pharmaceuticals review credits it explicitly, describing how Dalmasso and colleagues "proposed a non-receptor-dependent immunoregulatory effect of KPV, mediated by a transporter normally expressed in the small bowel and induced in colitis." That transporter is PepT1. What KPV does after it is inside a cell remains the least resolved part — the downstream readouts reported across this literature overlap heavily with the parent hormone's, but overlap in readout is not identity of pathway.

PepT1: how a tripeptide gets in

PepT1 is a proton-coupled transporter for di- and tripeptides. The 2023 Cells review describes it as "an H+-coupled di/tripeptide transporter" primarily localised to the small intestine. Its evolved job is nutritional: absorbing the two- and three-residue fragments left over from protein digestion. Three facts about it, taken together, are the reason KPV research is gut research.

KPV fits the substrate window. PepT1 moves peptides of two or three residues. KPV is exactly three. A 13-residue hormone like α-MSH is not a candidate for this route at all, so this is a property the fragment has and the parent does not. The 2024 Frontiers in Pharmacology paper describes KPV as "a tripeptide (Lys-Pro-Val) which possesses anti-inflammatory properties, displaying a high affinity with PepT1."

The transporter is not evenly distributed, and inflammation changes it. This is the detail that carries the mechanistic argument. The Cells review notes that PepT1 "does not have constitutively high levels of expression at the colonic level but may increase if inflammatory stimuli are chronically present at the colonic level." The 2024 Frontiers paper puts it more bluntly: "PepT1 is not expressed in normal colonic epithelial cells, while it is abnormally overexpressed in inflammatory cells, such as colonic epithelial cells and macrophages."

That gives a selectivity that does not depend on the peptide at all. If the carrier is largely absent from healthy colon and induced in inflamed colon, anything moving through it concentrates where the transporter has appeared. The tissue does the targeting.

The primary claim traces to a 2008 Gastroenterology paper by Dalmasso and colleagues, titled "PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation." We verified that paper's bibliographic record but could not retrieve its text, so we describe it only as later reviews do — a proposed non-receptor-dependent effect mediated by a small-bowel transporter induced in colitis, or, in the 2023 Cells review's more guarded phrasing, a hypothesis that "KPV is internalised within intestinal cells via a transporter peptide (i.e., PepT1)."

Two consequences follow. The PepT1 story is a strong argument for a mechanism in the gut and a weak one anywhere else, because a transporter-based rationale cannot be transplanted to tissues where that transporter's expression has not been established; recovery-context claims for KPV rest on a thinner set of arguments, and peptides studied in healing and recovery models covers how those are usually framed. And once PepT1 is understood as an inflammation-induced carrier, KPV becomes useful as a targeting ligand rather than only as a candidate agent — which is how the 2024 Frontiers group used it, and a reason to read the modern literature carefully. A study in which KPV is the delivery vehicle is not a study of KPV's own activity.

The colitis model literature

Two rodent models carry most of the KPV evidence, and they are not interchangeable.

DSS colitis is chemically induced. Dextran sodium sulfate is given in the drinking water, where it damages the colonic epithelial barrier and provokes inflammation. It is quick, reproducible and largely epithelial in origin. In its acute form the animals receive DSS continuously for about a week; the 2024 Frontiers work used male C57BL/6 mice for that, and produced a chronic version by cycling DSS-containing water with plain water over three rounds. It is a model of intestinal inflammation, not of human inflammatory bowel disease — acute, chemically driven and reversible in ways the human condition is not.

CD45RB-high transfer colitis is immune-driven. A naive T-cell population is adoptively transferred into lymphopenic recipients, where the absence of regulatory counterbalance produces a chronic, T-cell-mediated colitis. The value of having both models is that a compound working only in the chemical one might simply be protecting epithelium.

The 2008 Inflammatory Bowel Diseases study by Kannengiesser and colleagues used both, aiming "to investigate the therapeutic potential of the melanocortin-derived tripeptide α-MSH(11–13) (KPV) and its mode of action in 2 models of intestinal inflammation." In the paper's own words: in DSS colitis, "treatment with KPV led to earlier recovery and significantly stronger regain of body weight," with inflammatory infiltrates "significantly reduced" histologically, "confirmed by the significant reduction of MPO activity in colonic tissue" — myeloperoxidase being a standard proxy for neutrophil infiltration. In the transfer model, "KPV treatment of transfer colitis led to recovery, regain of body weight, and reduced inflammatory changes histologically."

Later work is mostly formulation work. A 2017 Molecular Therapy paper from the Merlin group is titled "Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis" — we verified that record bibliographically but did not retrieve its text, so we characterise it no further than its title. The 2024 Frontiers in Pharmacology study built a PepT1-targeted nanodrug from KPV co-assembled with the immunosuppressant FK506, and measured a broad readout panel spanning disease scoring, histology, cytokines, oxidative markers, tight-junction proteins and immune-cell markers — itemised in the table below.

Read that last column before the third. In two of these four studies KPV is not the variable being tested — it is part of a delivery system. That is a reasonable thing for a peptide to be, but it means the modern literature is thinner on KPV pharmacology than a raw publication count suggests.

The antimicrobial reports

Separately from the inflammation work, α-MSH peptides have been reported to have direct antimicrobial activity. The source is a single paper: a 2000 study in the Journal of Leukocyte Biology by Cutuli, Cristiani, Lipton and Catania, whose reasoning starts from anatomy. "The presence of the ancient antiinflammatory peptide α-melanocyte-stimulating hormone [α-MSH (1–13), SYSMEHFRWGKPV] in barrier organs such as gut and skin suggests a role in the nonspecific (innate) host defense." The authors tested both the full hormone and "its carboxy-terminal tripeptide (11–13, KPV)" against two organisms: Staphylococcus aureus and Candida albicans.

What they report: "α-MSH peptides significantly inhibited S. aureus colony formation and reversed the enhancing effect of urokinase on colony formation. Antimicrobial effects occurred over a broad range of concentrations including the physiological (picomolar) range. Small concentrations of α-MSH peptides likewise reduced viability and germ tube formation of the yeast C. albicans." Germ tube formation marks the yeast-to-hyphal switch associated with Candida invasiveness.

They also propose a mechanism and test it: cAMP. "This messenger was significantly augmented in peptide-treated yeast and the potent adenylyl cyclase inhibitor dideoxyadenosine (ddAdo) partly reversed the killing activity." Partly, not fully — the paper's own hedge, worth preserving. The most interesting observation is that anti-inflammatory agents typically impair pathogen clearance, whereas here "α-MSH peptides did not reduce killing but rather enhanced it" by human neutrophils.

The necessary caveat: this is one in-vitro paper, from 2000, on two organisms, and we did not retrieve an independent replication. It is a real published finding, not a body of evidence.

How large the literature actually is

It is easy to make any peptide sound well-studied by listing its papers. A better calibration is to count them. A PubMed search via the NCBI E-utilities interface for KPV tripeptide, run for this guide on 10 August 2026, returned 26 records. A Europe PMC search for KPV PepT1 colitis returned a hit count of 29. Scanning the top of that Europe PMC result set, most entries are nanomedicine and drug-delivery reviews — oral nanomedicine for IBD, albumin nanoparticle systems, gastrointestinal biological barriers — in which KPV appears as a targeting ligand or a worked example rather than as the subject.

The honest characterisation is a small field, dominated by one disease context, with a meaningful share of its recent output belonging to delivery engineering rather than peptide pharmacology. KPV is not obscure, but it is not deeply studied either.

That is part of why KPV shows up more often inside blends than on its own. The reasoning behind that packaging decision — and its costs — is covered in why peptides are blended; the four-component case is the KLOW blend. Where a protocol needs the tripeptide isolated so an observation can be attributed to it, KPV is stocked as a single-component vial.

What the evidence does not establish

This section is deliberately longer than the positive findings.

There is no human interventional data. Nothing in the sources retrieved here reports a controlled trial of KPV in people. The 2023 Cells review states the position directly: "human experiences are primarily anecdotal. Much of the available evidence is, in fact, preclinical." Every finding on this page comes from cultured cells or from mice.

The animal models are models. DSS colitis is chemically induced barrier damage in a genetically uniform, young rodent; transfer colitis requires a lymphopenic recipient with no human counterpart. Both are engineered to be reproducible, which is exactly what makes them unlike the heterogeneous chronic disease they stand in for. A compound that improves a disease activity index in DSS colitis has demonstrated an effect in DSS colitis.

In several of the strongest results, KPV is not the only variable. The 2024 Frontiers nanodrug co-assembles KPV with the immunosuppressant FK506; the improvements reported cannot be attributed to the tripeptide alone, and the study was not designed to do so. The 2017 Molecular Therapy work is, by its title, a delivery study.

The mechanism is not settled. Reviews describe MC1R-dependent and -independent mechanisms as both probably operating, and the receptor-independent pathway remains uncharacterised. "Acts independently of melanocortin receptors" is stronger than the data supports; so is "acts through MC1R." The dissociation of anti-inflammatory from pigmentary activity is likewise a review-level statement in the sources retrieved, not something verified here against a head-to-head assay.

The transporter argument does not generalise. PepT1 is described as an intestinal di/tripeptide carrier, largely absent from healthy colon and induced under chronic inflammatory stimulus. That is a strong rationale for gut work and none at all for skin, tendon, joint or systemic applications.

Two primary papers were not read in full for this guide. We verified the bibliographic records for Dalmasso 2008 (Gastroenterology) and Xiao 2017 (Molecular Therapy) — authors, journal, volume, pages, DOI — but the full texts sat behind access controls. Their contents are described here only as later reviews describe them, or not at all. Any specific figure attributed to those papers elsewhere should be checked against the papers themselves.

The antimicrobial evidence is one study. Two organisms, in vitro, published in 2000, with a partially reversible cAMP mechanism. Suggestive, not a characterisation. Replication is thin across the field generally: the two 2008 colitis papers converge on a similar conclusion, which is reassuring, but a literature of this size cannot support strong claims about effect size, and publication bias toward positive results is a live concern in any small preclinical field.

Identity and purity are lot-specific. No published paper speaks to the contents of any particular vial. Whether a given material is KPV, and whether it is the free acid or the amide, is established by that lot's analytical certificate and nowhere else.

Frequently asked questions

What does KPV stand for? Nothing — it is the sequence written in single-letter code: lysine, proline, valine. It is the C-terminal tripeptide of α-MSH, whose 13-residue sequence is SYSMEHFRWGKPV, which is why it is also written α-MSH(11–13).

Is KPV the same thing as α-MSH? No. It is three of the hormone's thirteen residues. Reviews describe the C-terminal tripeptide as retaining anti-inflammatory properties "with no pigmentary effects," which is the reason it is studied separately rather than as a substitute for the parent.

Why is KPV studied mainly in gut models? Because of PepT1, a proton-coupled di- and tripeptide transporter of the intestinal epithelium. A three-residue peptide falls inside that transporter's substrate range, and published work reports the transporter being scarce in healthy colon and induced in inflamed tissue. That is where the mechanistic argument is strongest, and the research followed it.

Does KPV work through melanocortin receptors? Partly, at most. A 2008 study reported that KPV retained a protective effect in mice whose melanocortin-1 receptor is nonfunctional, and a 2023 review concludes that both MC1R-dependent and MC1R-independent mechanisms are probably operating in experimental colitis. The receptor-independent pathway has not been identified.

Has KPV been tested in humans? No human interventional data appeared in the sources retrieved for this guide. A 2023 review of melanocortins in inflammatory bowel disease states that human experience is primarily anecdotal and that most of the available evidence is preclinical.

Why does KPV appear in blends so often? Because its proposed mechanism — damping inflammatory signalling — is different from the repair-associated mechanisms of peptides it is usually packaged with, which makes for a tidy-sounding rationale. Tidy-sounding is not tested; no study of those combinations exists. The trade-offs are covered in why peptides are blended and the four-component case in the KLOW guide.

Is KPV approved for human use? No. KPV is not an approved drug and not a dietary supplement. All Patriot Labs products are sold strictly for in-vitro research and laboratory use only, and are not for human or veterinary consumption.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes peptide chemistry and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.